In a human study, antioxidant MitoQ combats vascular aging
The mitochondrial antioxidant MitoQ has shown promise in treating some aspects of vascular ageing.
Since Denham Harmon’s 1956 formulation of the theory of free radicals, antioxidant-based therapies to prevent the effects of ageing have a long and rich history. This long history of antioxidants has had mixed results. Studies have shown efficacy or lack thereof, and even adverse health effects in some cases. In many of these studies, the effects of high doses naturally occurring antioxidants were studied. Due to their poor bioavailability, many of these natural compounds require high doses.
Scientists developed a synthetic version of Coenzyme Q10 because its bioavailability was poor. Coenzyme Q10 is a naturally occurring antioxident that occurs in cells. Its bioavailability decreases as we age. MitoQ is a synthetic form of Coenzyme Q10 that has a similar structure to its naturally occurring counterpart. However, it contains phosphonium triphenyl phosphate, which makes this derivative two to three times more permeable than the natural form. MitoQ seems to do most of its work in mitochondria by soaking reactive molecules generated by respiration that can damage lipids or proteins.